Halmstad, Sweden, November 18, 2025 – Redsense Medical AB (publ) ("Redsense'''' or "the Company") today announces that the Company will conduct a pilot study in collaboration with a global leading dialysis care provider at a partner clinic in Berlin, Germany, starting in December 2025. The study will evaluate the Redsense Blood Leakage Alarm system in a real-world clinical environment and generate updated data on usability, risk reduction of blood leakage and workflow integration.

"Collaborating with one of the leading clinical operators in the European dialysis market marks another important step in strengthening the clinical evidence base for our solution and expanding our footprint in Europe. This pilot will give us valuable, up-to-date clinical data and further insight into the integration of our technology in everyday dialysis practice." says Sebastien Bollue, CEO of Redsense Medical AB.

The partnering operator is one of Europe’s largest dialysis providers and plays an important role in advancing clinical standards in hemodialysis care. The study, scheduled to start in December 2025 and run during the first half of 2026 at a partner clinic in Berlin will use Redsense’s systems, which will be provided to the clinic on a loan basis, in approximately 150-200 hemodialysis treatments. The study is expected to result in a scientific publication, summarizing findings that will support the continued clinical validation, adoption and recommendation of Redsense’s technology in the European market.

Contact information

For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862